Background and aims Continuing recalcitrance to therapy cements pancreatic cancer (PC)
as the most lethal malignancy, which is set to become the second leading cause of cancer …

Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with
two broad lineages referred to as classical (pancreatic) and squamous. We find that these …

A list of contributors will be published in full upon acceptance of the manuscript. We thank
William Shen*, Antonio Pea*, Alessandra Pulvirenti*, all the members and administrative staff …

Objective Immunotherapy for the treatment of pancreatic ductal adenocarcinoma (PDAC)
has shown limited efficacy. Poor CD8 T-cell infiltration, low neoantigen load and a highly …

FOLFIRINOX, a combination of chemotherapy drugs (Fluorouracil, Oxaliplatin, Irinotecan -FOI),
provides the best clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients. …

Objective Cytotoxic agents are the cornerstone of treatment for patients with advanced
intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that …

Background: The long-term outcomes following surgical resection for pancreatic ductal
adenocarcinoma (PDAC) remains poor, with only 20% of patients surviving 5 years after …

Disrupted chromatin regulatory processes contribute to the development of cancer, in particular
pancreatic ductal adenocarcinoma. The assay for transposase accessible chromatin with …

Objective Cytotoxic agents are the cornerstone of treatment for patients with advanced
intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that …

Pancreatic cancer is characterised by the prevalence of oncogenic mutations in KRAS. Previous
studies have reported that altered Kras gene dosage drives progression and metastatic …